CCO Treatment Updates

Tumor Immunology: Treatment Approaches With Immunotherapies in Human Cancer

Immunology for the Oncologist: Historical Review of Immune Dysregulation and Immune Strategies

Module 1 of 3

Program Director: John M. Kirkwood, MD

Faculty:

F. Stephen Hodi, MD
  • F. Stephen Hodi, MD

CME CREDIT INFORMATION

Release Date: 10/15/07

Expiration Date: 10/14/08


Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Status: Please log in to view status
Begin the Module

F. Steven Hodi, MD, provides a historical look at previously used immunotherapy strategies and the novel and emerging strategies being employed today. Also included is a review of immune dysregulation that occurs in oncogenesis.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the principle of and clinical evidence for immune surveillance
  • Explain the process of immunoediting
  • Summarize current immunotherapy strategies
  • Identify monoclonal antibodies currently approved or under evaluation for the treatment of cancer

Current Challenges in Cancer Immunotherapy

Module 2 of 3

Program Director: John M. Kirkwood, MD

Faculty:

Cassian Yee, MD
  • Cassian Yee, MD

CME CREDIT INFORMATION

Release Date: 10/17/07

Expiration Date: 10/16/08


Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Status: Please log in to view status
Begin the Module

Cassian Yee, MD, highlights considerations of cancer types for immunotherapy, the optimal patient selection strategies involved, and managing adverse events.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss the mechanisms by which tumors escape immune surveillance
  • Summarize antitumor immunotherapies currently in development
  • Cite malignancies for which immunotherapeutic strategies are being developed
  • Describe toxicities associated with immunotherapies

New Directions in Cancer Immunotherapy

Module 3 of 3

Faculty:

John M. Kirkwood, MD
  • John M. Kirkwood, MD

CME CREDIT INFORMATION

Release Date: 11/15/07

Expiration Date: 11/14/08


Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Status: Please log in to view status
Begin the Module

John M. Kirkwood, MD, describes novel immunotherapy approaches and how and when they should be combined with traditional treatment paradigms. The concept of immune surveillance is also discussed.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss anti–CTLA-4 strategies in the treatment of cancer
  • Summarize monoclonal antibodies currently approved or under evaluation for the treatment of cancer
  • Describe immunotherapeutic vaccines, including whole tumor cell, peptide, and dendritic cell vaccines
  • Describe toxicities associated with immunotherapies

CCO Slideset

Evolving Approaches in Cancer Immunotherapy


Comprehensive downloadable slideset on novel approaches in cancer immunotherapy.


Format: Microsoft PowerPoint (.ppt) | File size: 753 KB


Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grant provided by:

Educational grants support only the CME-certified components of this program.